Month: April 2022

Studies provide insight into bifunctional molecular mechanism and first in vivo demonstration of immunomodulatory imide drug (IMiD) activity of NX-2127, resulting in robust tumor cell killing Animal models of adoptive cell therapy support the use of NX-0255 in the production of an investigational drug-enhanced TIL therapy, DeTIL-0255 SAN FRANCISCO, April 08, 2022 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced the presentation of preclinical data that support the clinical development of investigative therapies NX-2127 and DeTIL-0255, for the treatment of B-cell malignancies and solid tumors, respectively, at the American Association for Cancer Research (AACR) Annual Meeting. The meeting is being held from April...

CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the presentation of biomarker signature data from two studies evaluating vidutolimod, a first-in-class, immunostimulatory, noninfectious virus-like particle (VLP) containing a CpG-A Toll-like receptor 9 (TLR9) agonist. The first study evaluated vidutolimod in patients with advanced anti-PD-(L)1 refractory melanoma who received intratumoral vidutolimod monotherapy or in combination with intravenous pembrolizumab, and the second evaluated patients with anti-PD-(L)1 refractory non-small cell lung cancer (NSCLC) who received vidutolimod and atezolizumab. The...

BOSTON, April 08, 2022 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage oncology focused biotechnology company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported new preclinical data on CTX-8371, a next generation bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1 and exhibits a unique MOA that involves cleavage of cell surface PD-1, at the American Association for Cancer Research (AACR) Annual Meeting, which is being held April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana (Abstract Number: 5027; Session Title: Combination Immunotherapies / Therapeutic Antibodies). Key data presented includes the following:Treatment with CTX-8371 leads to PD-1 loss from the surface of intra-tumoral T cells...

Findings presented today at AACR Annual Meeting detail Calithera discovery of VPS4A inhibitors and their potential as a therapeutic approach in numerous solid tumor cancers VPS4A and VPS4B are gene paralogs that show strong synthetic lethal interaction SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, shared new data today from the company’s preclinical synthetic lethality program. The findings, which are now available as an e-poster and will be presented live on April 11 at the American Association for Cancer Research (AACR) Annual Meeting 2022 (Abstract #1816), validate the synthetic lethal interaction between the gene paralogs vacuolar protein sorting-associated protein 4A (VPS4A) and 4B (VPS4B), and provide...

Akropolis Group, leader in the development and management of shopping and entertainment centres in the Baltic States, based on its audited consolidated financial results, has received revenue of EUR 81 million and earned profit of EUR 57.2 million EBITDA (Earnings before tax, interest, depreciation and amortisation) last year, which is, respectively, 5% and 6% more than in 2020. The group announced its last year’s audited results and revealed that it saw a positive change in all key financial indicators in 2021. After the acquisition of the shopping centre Alfa in Riga last November, the fair value of Akropolis Group portfolio grew by 28% to EUR 1.023 billion in 2021. This year, shopping centre Alfa was fully integrated into the structure of Akropolis Group, changing its name into Akropole Alfa. “For the most part of the first half of...

Invalda INVL’s equity at the end of 2021 was EUR 121.2 million, or EUR 10.32 per share, and increased 45% compared to the end of 2020. Invalda INVL’s net profit last year was EUR 37.5 million, which is 7 times more than in 2020 when it was EUR 5.3 million. “As we look further in 2022, we face a new common concern for the peace and long-term order that allows people to live, work and create opportunities to prosper both safely and freely in Central and Eastern Europe. This is clearly of paramount importance. While we fully support Ukraine, we are aware that it is very challenging to predict what the coming years will  bring and when the situation may stabilise. There are many questions that remain unanswered. How  will the ongoing situation affect individual countries and sectors of their economies, how will commodities prices and logistical...

Valoe Corporation                Stock Exchange Release 8 April 2022 at 18.00 Finnish time                                  The Board of Directors of Valoe Corporation (the “Company”) has, pursuant to the terms and conditions of the financing arrangement between Valoe Corporation and RiverFort Global Opportunities Pcc Limited (“RiverFort”) announced on 30 July 2021, resolved to approve the request of RiverFort i) to convert a proportion of EUR 250,000 of the outstanding amount of the RiverFort financing arrangement into the shares in the Company at a conversion price of EUR 0.07866 per share, and ii) to convert a proportion of EUR 159,083 of the outstanding amount (including principal and interest) of the RiverFort financing arrangement into the shares in the Company at a conversion price of EUR 0.07961 per share. The conversions...